Bristol’s $5.3 Billion Amylin Deal Heralds Acquisition Hunger

July 2, 2012 | Bristol-Myers Squibb annoucned a $5.3 billion deal to buy diabetes drugmaker Amylin Pharmaceuticals, gives BMS immediate access to a market of growing medical need, while heralding a burgeoning hunger among pharmaceutical companies for acquisitions. The agreement is the second announced this year for Bristol, and the largest for the industry. It comes after the blood- thinner Plavix, Bristol’s top seller in 2011 at $7.1 billion, faced generic competition for the first time in May. Bloomberg